Open Access (to research, data, journals, etc)
Transparency
Signatures to the petition to President Obama, regarding transparency of ACTA
Signatures to the petition to President Obama, regarding transparency of ACTA Back to the petition US signatories Knowledge Ecology International David Bollier, Onthecommons.org U.S. Public Interest Research Group Essential Action Health Action International (HAI) Global Public Citizen Ellen Miller, Sunlight… Continue Reading
Letter to President Obama on ACTA transparency
The following is a letter that was sent on November 3, 2009 to President Obama, asking that the negotiations regarding ACTA be made more transparent. For more background on ACTA and the disputes over transparency, see KEI website on ACTA… Continue Reading
Letter to President Obama on ACTA Transparency
The following is a letter that was sent on November 3, 2009 to President Obama, asking that the negotiations regarding ACTA be made more transparent. For more background on ACTA and the disputes over transparency, see KEI website on ACTA… Continue Reading
Legislation on transparency of R&D costs in biopharmaceutical sector
This page features KEI blog posts, testimony, comments, and research on the transparency of the costs of research and development in the pharmaceutical sector. United States Transparency Legislation 16 March 2017: KEI testifies before a Maryland House of Delegates Subcommittee… Continue Reading
Transparency
In the area of Transparency, KEI works on several different topics, including for example: Norm setting. KEI has advocated access to meeting venues, timely disclosures of negotiating texts, and the use of webcasting of meetings, among other measures. Trade negotiations… Continue Reading
2017: NIH non-response response to KEI and MSF comments on the proposed exclusive license of Zika vaccine patents to PaxVax
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On November 30, 2017, KEI has received a response from the National Institute of Allergy and Infectious Diseases regarding our previous joint comments with MSFon the proposed exclusive… Continue Reading
KEI Comments on the Draft Concept Note Concerning the WHO General Programme of Work
On October 13, 2017, KEI submitted comments to the WHO regarding the Draft Concept Note towards the WHO’s 13th General Programme of Work. The Draft Concept Note is available here: http://www.who.int/about/draft-concept-note_13th-programme-work.pdf
The text of KEI’s comments follow below, and a PDF is available here.
Friday, 13 October 2017
Dear Dr. Tedros,
SEARO RC70: Statement of Knowledge Ecology International on Access to Medicines
Knowledge Ecology International (KEI) delivered the following statement during discussions at the WHO South East Asia Region (SEARO) Regional Committee on Access to Medicines on 9 September 2017 in the Maldives.
(Photo taken by Cristina Bajar)
Intervention of Knowledge Ecology InternationalSeventieth Session of the Regional Committee – SEARO: 8.3 Access to medicines – SEA/RC70/9
Saturday, 9 September 20172017: miRecule/NIH license on MicroRNA Therapeutics for Treating Squamous Cell Carcinomas
Attached (PDF file here) are the KEI comments on the proposed NIH exclusive license to miRecule for MicroRNA Therapeutics for Treating Squamous Cell Carcinomas.
The seven page letter concludes with these words: